{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:14:08Z","timestamp":1788786848152,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2022\/05199-9"],"award-info":[{"award-number":["2022\/05199-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/24304-0"],"award-info":[{"award-number":["2017\/24304-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.pbb.2024.173919","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T17:10:12Z","timestamp":1732813812000},"page":"173919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Acute cannabidiol treatment reverses behavioral impairments induced by embryonic valproic acid exposure in male mice"],"prefix":"10.1016","volume":"247","author":[{"given":"J.F.C.","family":"Pedrazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.M.","family":"Ponciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.R.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"Zuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Del Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.S.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pbb.2024.173919_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"de Almeida","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.pbb.2024.173919_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.pbb.2024.173919_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14728214.2024.2306290","article-title":"Cannabinoid treatment for the symptoms of autism spectrum disorder","volume":"29","author":"Aran","year":"2024","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.pbb.2024.173919_bb0020","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems\u2014a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pbb.2024.173919_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol. Autism."},{"key":"10.1016\/j.pbb.2024.173919_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism."},{"key":"10.1016\/j.pbb.2024.173919_bb0035","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and comorbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neuron.2012.07.022","article-title":"Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice","volume":"76","author":"Bhattacharya","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2024.173919_bb0045","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of \u03b4-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0055","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s10803-011-1284-z","article-title":"Evidence-based behavioral interventions for repetitive behaviors in autism","volume":"42","author":"Boyd","year":"2012","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pbb.2024.173919_bb0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/archpsyc.1992.01820030038005","article-title":"Gating and habituation of the startle reflex in schizophrenic patients","volume":"49","author":"Braff","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archgenpsychiatry.2011.38","article-title":"Epidemiology of autism spectrum disorders in adults in the community in England","volume":"68","author":"Brugha","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0070","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.pbb.2024.173919_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13229-018-0241-5","article-title":"A pilot dose finding study of pioglitazone in autistic children","volume":"26","author":"Capano","year":"2018","journal-title":"Mol. Autism."},{"key":"10.1016\/j.pbb.2024.173919_bb0080","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.pbb.2024.173919_bb0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00401-006-0085-5","article-title":"Minicolumnar abnormalities in autism","volume":"112","author":"Casanova","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.pbb.2024.173919_bb0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0b013e32833b33c5","article-title":"Cannabidiol inhibitory efect on marble-burying behavior: involvement of CB1 receptors","volume":"21","author":"Casarotto","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0095","first-page":"1","article-title":"Cannabis use during adolescent development: susceptibility to psychiatric illness","volume":"4","author":"Chadwick","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pbb.2024.173919_bb0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","article-title":"Endocannabinoid signaling in autism","volume":"12","author":"Chakrabarti","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pbb.2024.173919_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.psychres.2017.09.016","article-title":"Meta-analysis of sensorimotor gating in patients with autism spectrum disorders","volume":"262","author":"Cheng","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173919_bb0115","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age","volume":"9","author":"Crippa","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pbb.2024.173919_bb0120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nprot.2006.20","article-title":"Digging and marble burying in mice: simple methods for in vivo identification of biological impacts","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.pbb.2024.173919_bb0125","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pbb.2024.173919_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00008877-200006000-00006","article-title":"Animal models for the negative symptoms of schizophrenia","volume":"11","author":"Ellenbroek","year":"2000","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0140","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.3389\/adar.2023.11163","article-title":"Acute cannabidiol treatment enhances social interaction in adult male mice","volume":"3","author":"Ferreira","year":"2023","journal-title":"Adv. Drug Alcohol Res."},{"key":"10.1016\/j.pbb.2024.173919_bb0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/tera.1420380403","article-title":"Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite","volume":"38","author":"Finnell","year":"1988","journal-title":"Teratology"},{"key":"10.1016\/j.pbb.2024.173919_bb0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuropharm.2018.03.001","article-title":"The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling","volume":"135","author":"Foga\u00e7a","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0155","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","article-title":"Pharmacological and therapeutic properties of Cannabidiol for epilepsy","volume":"79","author":"Franco","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pbb.2024.173919_bb0160","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2214.2006.00616.x","article-title":"Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems","volume":"32","author":"Garstang","year":"2006","journal-title":"Child Care Health Dev."},{"key":"10.1016\/j.pbb.2024.173919_bb0165","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/genes14030677","article-title":"The autism spectrum: behavioral, psychiatric and genetic associations","volume":"14","author":"Genovese","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pbb.2024.173919_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu041","article-title":"Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice","volume":"18","author":"Gomes","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0175","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02244012","article-title":"Antianxiety effect of cannabidiol in the elevated plus-maze","volume":"100","author":"Guimar\u00e3es","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0180","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1254\/jphs.12025SC","article-title":"Effect of prenatal valproic acid exposure on cortical morphology in female mice","volume":"118","author":"Hara","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2024.173919_bb0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbr.2015.04.022","article-title":"Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model","volume":"289","author":"Hara","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2024.173919_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109637","article-title":"Cannabidiol attenuates aggressive behavior induced by social isolation in mice: involvement of 5-HT1A and CB1 receptors","volume":"94","author":"Hartmann","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatr."},{"issue":"12","key":"10.1016\/j.pbb.2024.173919_bb0195","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2309359","article-title":"Risk of autism after prenatal Topiramate, valproate, or lamotrigine exposure","volume":"390","author":"Hern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2024.173919_bb0200","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism."},{"key":"10.1016\/j.pbb.2024.173919_bb0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S1461145711001714","article-title":"Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid","volume":"16","author":"Kataoka","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0215","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41398-023-02374-w","article-title":"Comorbidities in autism spectrum disorder and their etiologies","volume":"13","author":"Khachadourian","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.nlm.2021.107462","article-title":"Amini AE, Hosseinmardi N, Behzadi G, Janahmadi M. 5-HT7 receptor activation rescues impaired synaptic plasticity in an autistic-like rat model induced by prenatal VPA exposure","volume":"183","author":"Khodaverdi","year":"2021","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.pbb.2024.173919_bb0225","doi-asserted-by":"crossref","first-page":"867","DOI":"10.5535\/arm.2011.35.6.867","article-title":"Neurodevelopmental disorders of children screened by the infantile health promotion system","volume":"35","author":"Kim","year":"2011","journal-title":"Ann. Rehabil. Med."},{"key":"10.1016\/j.pbb.2024.173919_bb0230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.psychres.2017.01.017","article-title":"What is the prevalence of autism spectrum disorder and ASD traits in psychosis? A systematic review","volume":"250","author":"Kincaid","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2024.173919_bb0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamapediatrics.2019.4368","article-title":"Association of comorbid mood and anxiety disorders with autism spectrum disorder","volume":"174","author":"Kirsch","year":"2020","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.pbb.2024.173919_bb0240","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0245","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0250","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(13)61539-1","article-title":"Autism. Autism","volume":"383","author":"Lai","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173919_bb0255","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0260","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.neuron.2011.05.015","article-title":"Rare de novo and transmitted copy-number variation in autistic spectrum disorders","volume":"70","author":"Levy","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2024.173919_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0270","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10803-006-0123-0","article-title":"Comorbid psychiatric disorders in children with autism: interview development and rates of disorders","volume":"36","author":"Leyfer","year":"2006","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pbb.2024.173919_bb0275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb1005","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","volume":"31","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.635763","article-title":"Is Cannabidiol during neurodevelopment a promising therapy for schizophrenia and autism spectrum disorders?","volume":"11","author":"Loss","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2024.173919_bb0285","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5607\/en.2015.24.4.285","article-title":"Exploring the validity of valproic acid animal model of autism","volume":"24","author":"Mabunga","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.pbb.2024.173919_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107176","article-title":"Cannabidiol and positive effects on object recognition memory in an in vivo model of Fragile X Syndrome: obligatory role of hippocampal GPR55 receptors","volume":"203","author":"Manduca","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2024.173919_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0091-3057(91)90349-7","article-title":"Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs","volume":"40","author":"Martin","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173919_bb0300","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.3390\/ijms21218290","article-title":"An overview of the main genetic, epigenetic and environmental factors involved in autism spectrum disorder focusing on synaptic activity","volume":"21","author":"Masini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2024.173919_bb1000","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"Hashish-I the structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron"},{"key":"10.1016\/j.pbb.2024.173919_bb0305","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.pbb.2024.173919_bb0310","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1111\/bph.14435","article-title":"Sex-specifc autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling","volume":"175","author":"Melancia","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0315","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijdevneu.2019.05.006","article-title":"Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-\u03b3 agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats","volume":"76","author":"Mirza","year":"2019","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.pbb.2024.173919_bb0320","first-page":"103","article-title":"Molecular targets of the phytocannabinoids: a complex picture","volume":"103","author":"Morales","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"key":"10.1016\/j.pbb.2024.173919_bb0325","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.neuroscience.2010.02.058","article-title":"Transient receptor potential vanilloid 1 channels control acetylcholine\/2-arachidonoylglicerol coupling in the striatum","volume":"167","author":"Musella","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2024.173919_bb0330","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.expneurol.2017.04.017","article-title":"The valproic acid-induced rodent model of autism","volume":"299","author":"Nicolini","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2024.173919_bb0335","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0091-3057(91)90590-X","article-title":"Evaluation of marble-burying behavior as a model of anxiety","volume":"38","author":"Njung\u2019e","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173919_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reprotox.2009.02.014","article-title":"Valproic acid in pregnancy: how much are we endangering the embryo and fetus?","volume":"28","author":"Ornoy","year":"2009","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.pbb.2024.173919_bb0345","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/bph.15003","article-title":"Cannabidiol improves survival and behavioral comorbidities of Dravet syndrome in mice","volume":"177","author":"Patra","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0350","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110352","article-title":"Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum","volume":"111","author":"Pedrazzi","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0360","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-022-06196-4","article-title":"Cannabidiol for the treatment of autism spectrum disorder: hope or hype?","volume":"239","author":"Pedrazzi","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb1010","doi-asserted-by":"crossref","first-page":"173879","DOI":"10.1016\/j.pbb.2024.173879","article-title":"Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission","volume":"245","author":"Pedrazzi","year":"2024","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2024.173919_bb0365","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.neubiorev.2021.11.031","article-title":"The role of the endocannabinoid system as a therapeutic target for autism spectrum disorder: lessons from behavioral studies on mouse models","volume":"132","author":"Pietropaolo","year":"2022","journal-title":"Neurosci. Biobehav. Ver."},{"key":"10.1016\/j.pbb.2024.173919_bb0370","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","article-title":"Cannabidiol as a suggested candidate for treatment of autism spectrum disorder","volume":"8","author":"Poleg","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-020-02478-7","article-title":"A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report","volume":"14","author":"Ponton","year":"2020","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.pbb.2024.173919_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.148013","article-title":"Alterations in the intrinsic discharge activity of CA1 pyramidal neurons associated with possible changes in the NADPH diaphorase activity in a rat model of autism induced by prenatal exposure to valproic acid","volume":"1792","author":"Rahdar","year":"2022","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.pbb.2024.173919_bb0385","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1017\/S0012162205001076","article-title":"Characteristics of fetal anticonvulsant syndrome associated autistic disorder","volume":"47","author":"Rasalam","year":"2005","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.pbb.2024.173919_bb0390","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ntt.2013.01.004","article-title":"In utero exposure to valproic acid and autism--a current review of clinical and animal studies","volume":"36","author":"Roullet","year":"2013","journal-title":"Neurotoxicol. Teratol."},{"issue":"5","key":"10.1016\/j.pbb.2024.173919_bb0395","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.neuron.2011.05.025","article-title":"Solving the autism puzzle a few pieces at a time","volume":"70","author":"Schaaf","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2024.173919_bb0400","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.npp.1300518","article-title":"Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism","volume":"30","author":"Schneider","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0405","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"24","author":"Schubart","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0410","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ptr.2625","article-title":"Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders","volume":"23","author":"Scuderi","year":"2009","journal-title":"Phyther. Res."},{"key":"10.1016\/j.pbb.2024.173919_bb0415","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0420","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.182","article-title":"Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid","volume":"6","author":"Servadio","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173919_bb0425","article-title":"Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors","volume":"156","author":"Silva","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2024.173919_bb0430","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbi.2018.09.014","article-title":"Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPAR\u03b3 receptors","volume":"74","author":"Sonego","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pbb.2024.173919_bb0435","doi-asserted-by":"crossref","first-page":"1185737","DOI":"10.3389\/fnins.2023.1185737","article-title":"Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder","volume":"17","author":"Staben","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2024.173919_bb0440","article-title":"Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents","volume":"395-402","author":"Stepanova","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pbb.2024.173919_bb0445","doi-asserted-by":"crossref","first-page":"102","DOI":"10.9758\/cpn.2011.9.3.102","article-title":"Prepulse inhibition of startle response: recent advances in human studies of psychiatric disease","volume":"93","author":"Takahashi","year":"2011","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.pbb.2024.173919_bb0450","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pbb.2014.08.013","article-title":"Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism","volume":"126","author":"Takuma","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173919_bb0455","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0460","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00213-009-1466-y","article-title":"Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety","volume":"204","author":"Thomas","year":"2009","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2024.173919_bb0465","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1570159X22666231003121513","article-title":"Three decades of valproate: a current model for studying autism spectrum disorder","volume":"22","author":"Zarate-Lopez","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2024.173919_bb0470","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by \u03b49-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2024.173919_bb0475","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02244189","article-title":"Efects of cannabidiol in animal models predictive of antipsychotic activity","volume":"104","author":"Zuardi","year":"1991","journal-title":"Psychopharmacology"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724002132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724002132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:01:24Z","timestamp":1777474884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305724002132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":97,"alternative-id":["S0091305724002132"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173919","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute cannabidiol treatment reverses behavioral impairments induced by embryonic valproic acid exposure in male mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"173919"}}